Hercules Capital, Inc. (HTGC)
| Market Cap | 3.49B |
| Revenue (ttm) | 504.00M |
| Net Income (ttm) | 256.61M |
| Shares Out | 179.41M |
| EPS (ttm) | 1.52 |
| PE Ratio | 12.83 |
| Forward PE | 9.89 |
| Dividend | $1.88 (9.67%) |
| Ex-Dividend Date | Aug 12, 2025 |
| Volume | 1,080,558 |
| Open | 19.30 |
| Previous Close | 19.24 |
| Day's Range | 19.20 - 19.44 |
| 52-Week Range | 15.65 - 22.04 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 21.31 (+9.62%) |
| Earnings Date | Jul 31, 2025 |
About HTGC
Hercules Capital, Inc. is a business development company. The firm specializing in providing private equity, venture debt, and growth capital to privately held venture capital-backed companies at all stages of development from mid venture to expansion stage including select publicly listed companies and select special opportunity companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management ... [Read more]
Financial Performance
In 2024, Hercules Capital's revenue was $493.59 million, an increase of 7.15% compared to the previous year's $460.67 million. Earnings were $260.14 million, a decrease of -22.15%.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for HTGC stock is "Buy." The 12-month stock price target is $21.31, which is an increase of 9.62% from the latest price.
News
BDC Weekly Review: Tight Spreads Keep A Lid On Net Income
We take a look at the action in business development companies through the first week of August and highlight some of the key themes we are watching. BDCs underperformed despite strong early earnings,...
Hercules Capital: Attractive 9.7% Yield BDC, VC/Pre-IPO Growth
Business Development Companies offer income-focused investors access to big-yield private credit opportunities, traded on the public market. Hercules Capital is a standout among the group for its diff...
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
CARY, N.C. , Aug. 8, 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restru...
Snappt Acquires Trigo to Enhance Applicant Trust Platform for Multifamily Housing, Secures $50M Growth Financing
LOS ANGELES--(BUSINESS WIRE)--Snappt, the leading platform for applicant trust in multifamily housing, today announced it has acquired Trigo, a company known for its breakthrough technology in verifyi...
Hercules Capital: A High-Yield Stock Worth Buying And Holding
The BDC investment at HTGC represents one of the best options for investors who want to generate long-term income. Q2 results beat expectations, with $0.50 NII covering the $0.47 dividend and confirmi...
Hercules Capital, Inc. (HTGC) Q2 2025 Earnings Call Transcript
Hercules Capital, Inc. (NYSE:HTGC) Q2 2025 Earnings Conference Call July 31, 2025 5:00 PM ET Company Participants Michael W. Hara - Managing Director of Investor Relations & Corporate Communications ...
Hercules Capital Reports Second Quarter 2025 Financial Results
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and establishe...
Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Second Quarter 2025
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty finance provider to innovative venture, growth and established ...
Hercules Capital's Wholly-Owned Investment Adviser Launches Fourth Institutional Private Credit Fund
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital” or the “Company”), the largest and leading specialty finance provider to innovative venture, gro...
Hercules Capital Announces Date for Release of Second Quarter 2025 Financial Results and Conference Call
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and establishe...
BDC Weekly Review: Should We Trust BDC NAVs?
We take a look at the action in business development companies through the first week of July and highlight some of the key themes we are watching. BDCs delivered a strong 3% total return this week, w...
Hercules Capital Receives Affirmed BBB- Investment Grade Corporate and Unsecured Credit Rating from Fitch Ratings, Inc.
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and establishe...
Hercules Capital: Better Entry Point, But Further Potential Economic Weakening Keeps Me At Bay
I maintain my Hold rating on Hercules Capital due to premium valuation, economic uncertainty, and recent earnings misses despite strong fundamentals. Dividend coverage remains solid, supported by spil...
17 Ideal 'Safer' Dividend Dogs To Buy Out Of 72 June Graham Value All-Stars
I use YCharts' Value Score and Ben Graham Formula Value All Stars, or GASV, to identify large-cap stocks offering strong value and dividend safety. Seventeen out of twenty-four "safer" lowest-priced D...
Hercules Capital: Buyable, But Proceed With Caution (Rating Downgrade)
Hercules Capital, Inc.'s focus on first-lien, floating rate debt in tech and life sciences offers stability, but growth will likely slow as rates fall. HTGC stock's 58% premium to NAV is both a risk a...
Hercules Capital Closes Upsized Institutional Notes Offering of $350.0 Million 6.000% Unsecured Notes due 2030
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), today announced that it has closed an upsized underwritten public offering of $350.0 million in a...
Hercules Capital: Growing Troubles Within Portfolio Warrants Caution
I maintain a hold rating on HTGC due to its premium valuation and rising concerns over portfolio quality and PIK interest income. HTGC's dividend yield remains attractive and well-covered, but increas...
Hercules Capital Prices Upsized Institutional Notes Offering of $350.0 Million 6.000% Notes due 2030
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), today announced that it has priced an upsized underwritten public offering of $350.0 million in a...
I'm Buying Up To 10% Yields For Recurring Income
I focus on the payback period and high-yield income, highlighting Hercules Capital and VICI Properties for faster capital recoupment and strong recurring income. HTGC stands out with a 10.4% yield, fi...
Fortress Income: 7-11% Yields To Make Money While You Sleep
Buying right and holding tight can be a winning investment strategy over in-vogue short-term strategies. EPD has strong fee-based earnings, strong balance sheet, and growth projects coming online, off...
Buy Any Of 18 Ideal 'Safer' May Dividend Dogs Out Of 70 Graham Value All-Stars (GVAS)
I use YCharts' Value Score and Ben Graham Formula to identify large-cap stocks offering strong value relative to profits, assets, and dividends. Eighteen of twenty-four 'safer' lowest-priced Dividend ...
Hercules Capital: Contrarian Buying Opportunity
Hercules Capital delivered decent Q1 results, with robust net investment income supporting its attractive dividend yield. The investment firm maintained excellent balance sheet quality, reinforcing co...
Hercules Capital: A Strong BDC Investment Pick (Rating Upgrade)
Hercules Capital is a top BDC choice for passive income investors, offering solid dividends supplemented by non-base distributions and strong credit quality. The BDC focuses on the technology sector, ...
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometab...
BDC Weekly Review: Bimodal Q1 Numbers Weigh On The Sector
We take a look at the action in business development companies through the first week of May and highlight some of the key themes we are watching. BDCs fell around 1.5% this week due to a couple of we...